Effect of Empagliflozin on Peritoneal and Kidney Function in End Stage Renal Disease
NCT05671991
·
clinicaltrials.gov ↗
PHASE4
Phase
RECRUITING
Status
30
Enrollment
OTHER
Sponsor class
Conditions
End Stage Renal Disease on Dialysis
Interventions
DRUG:
Empagliflozin 25 mg vs Placebo
DRUG:
Empagliflozin 10 MG
Sponsor
Yale University
Collaborators
[object Object]